[Clinical and therapeutic aspects in Tunisian patients with dystonia: a 5-year prospective study].
BACKGROUND
Studies of dystonia are heterogeneous and there are no studies on this disease in Tunisia. The aim of our study was to determine the frequency of dystonia in the hospital population, to identify different forms of dystonia according to age of onset, distribution, to determine etiologies and to describe treatment.


METHODS
We conducted a prospective study over a 5-year period (from January 2005 to November 2009) including all patients diagnosed with dystonia and followed at the Child and Adolescent Neurology Department and "Movement Disorders and Botulinum Toxin" consultation of the National Institute of Neurology of Tunis.


RESULTS
Two hundred patients were included (2.2% of our patients). Mean age was 26.4±21.4 years and sex ratio H:F 1.3. Consanguinity rate was 29%. Main features of dystonia were action dystonia (78.5%), generalized forms (47%) and secondary forms (58%). A pyramidal syndrome and other movement disorders were the most common signs associated with dystonia (36.5% and 33.5% respectively). In the group of secondary dystonia, mains etiologies were dystonia due to exogenic agent (56%), neuro-metabolic diseases (26%), hereditary degenerative disease (13%) and psychogenic dystonia (5%). Dystonia was primary in 44% (84 patients). Different treatments were used and a dramatic improvement in some patients was noted with levodopa and botulinum toxin injections. A multidisciplinary approach associated with medical treatment led to recovery or improved prognosis.


CONCLUSIONS
Very few studies have been devoted to reporting a large series of dystonic patients. Our study is the first to describe both primary and secondary dystonia in 200 Tunisian patients. The presence of familial dystonia in our country suggests a genetic origin. Further work including genetic analysis with a screening of known mutations responsible for dystonia and the informative families with unknown mutations would be useful. Specific studies designed to identify new genes causal in dystonia are needed.
Unité de recherche UR06/11, service de neurologie de l'enfant et de l'adolescent, institut national de neurologie de Tunis, rue Jébal-Lakhdhar, La Rabta Bab Saâdoun, 1007 Tunis, Tunisie.
H
H
Benrhouma
I
I
Kraoua
H
H
Klaa
A
A
Rouissi
I
I
Turki
N
N
Gouider-Khouja
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D002648:Child; D003241:Consanguinity; D004421:Dystonia / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D020271:Heredodegenerative Disorders, Nervous System / Q000150:complications; D006760:Hospitalization; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014416:Tunisia / Q000453:epidemiology
D018726:Anti-Dyskinesia Agents; D000978:Antiparkinson Agents; D007980:Levodopa; D001905:Botulinum Toxins